Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 286

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 286
---
 |     |       308 |   |
| Quest Diagnostics Incorporated |     | NYSE:DGX      |     |      19,250 |   |     |      9,252 |     |     1,773 |   |
| Exact Sciences Corporation     |     | NASDAQCM:EXAS |     |      12,877 |   |     |      2,500 |     |      (102 | ) |
| Eurofins Scientific SE         |     | ENXTPA:ERF    |     |      15,134 |   |     |      7,045 |     |     1,284 |   |
| Digital Healthcare Platforms   |     |               |     |             |   |     |            |     |           |   |
| American Well Corporation      |     | NYSE:AMWL     |     |         (71 | ) |     |        259 |     |      (226 | ) |
| Sharecare, Inc.                |     | NASDAQGS:SHCR |     |         266 |   |     |        442 |     |       (94 | ) |

____________ Notes:- (1)Figures in millions. (2)Based on closing share price as of March 13, 2024. While this comparable company analysis was used to subjectively evaluate the Business Combination, these metrics were not used to quantitatively arrive at the proposed valuation of the Company. The proposed valuation was not derived from a mechanical application of valuation metrics or a specific financial model. Rather, the valuation was proposed by the Company and reviewed by the APx Board in light of various qualitative and contextual considerations. In assessing the reasonableness of the proposed valuation, the APx Board considered, among other factors, the Company’s relative cash burn, product maturity, addressable market, and operational scalability. See “ Risk Factors — Risks Related to APx — APx did not obtain a fairness opinion in connection with the Business Combination, and consequently, you do not have assurance from an independent source that the consideration APx is paying for the Company is fair to APx from a financial point of view. Additionally, the valuation of the Company was proposed, and accepted, based on a number of subjective, qualitative factors, and no formal quantitative valuation exercise was performed.” This peer group reported a median fiscal year 2023 EBITDA (as a proxy for cash burn) of approximately $(77.0) million and a